The combination of acute phase marker monitoring and the "T2Candida" assay (name of the test) will represent an acceleration of the identification of the causative agent of mycotic infection, a significant improvement in the specificity and positive predictive value of this strategy in the diagnosis of invasive candidiasis and candidemia in ICU patients, thereby improving the clinical condition of patients and reducing the cost of specific antifungal therapy.
Age range
12 Months
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Acute-phase biomarkers dynamics - procalcitonin
Timeframe: 8 days
Acute-phase biomarkers dynamics - interleukin-6
Timeframe: 8 days
Acute-phase biomarkers dynamics - interleukin-10
Timeframe: 8 days
Acute-phase biomarkers dynamics - Presepsin
Timeframe: 8 days
Acute-phase biomarkers dynamics - C-reactive protein
Timeframe: 8 days
Acute-phase biomarkers dynamics - 1,3-β-D-glucan
Timeframe: 8 days
Acute-phase biomarkers dynamics - pentraxin 3
Timeframe: 8 days
T2Candida test
Timeframe: One-time measurement at the enrolment into the study
Lipopolysaccharide binding protein
Timeframe: One-time measurement at the enrolment into the study